Recent advances in treatment of heart failure.

Influence of Ivabradine on the Anticonvulsant Action of Four Classical Antiepileptic Drugs Against Maximal Electroshock-Induced Seizures in Mice. Neurochem Res (2017) 0.75

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 18.90

Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25

Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77

Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62

Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (2010) 8.17

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48

Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med (2013) 7.29

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03

Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2010) 4.88

Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med (2014) 4.13

The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2006) 4.10

Natriuretic peptides. J Am Coll Cardiol (2007) 3.91

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66

Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet (2009) 2.83

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (2010) 2.80

The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation (2014) 2.75

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA (2014) 2.30

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J (2011) 2.14

Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol (2009) 2.06

Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J (2011) 1.95

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol (2013) 1.89

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J (2012) 1.89

Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation (2003) 1.86

A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology (2003) 1.83

Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation (2014) 1.77

Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol (1996) 1.58

Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol (1994) 1.57

Impact of nesiritide on renal function and mortality in patients suffering from heart failure. Cardiovasc Drugs Ther (2009) 1.49

Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol (2002) 1.31

Evidence for local relaxin ligand-receptor expression and function in arteries. FASEB J (2006) 1.26

Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol (2009) 1.26

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail (2015) 1.25

Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res (2004) 1.20

Emerging role of relaxin in renal and cardiovascular function. Am J Physiol Regul Integr Comp Physiol (2004) 1.20

Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J (2006) 1.19

Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res (2003) 1.17

Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther (1995) 1.15

Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr (1988) 1.14

Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension (1998) 1.13

Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J (2005) 1.12

Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J (2011) 1.07

Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail (2007) 1.03

The vascular actions of relaxin. Adv Exp Med Biol (2007) 1.02

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J (2012) 1.02

Natriuretic peptides in vascular physiology and pathology. Int Rev Cell Mol Biol (2008) 1.01

Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail (2012) 1.00

'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol Ther (2006) 0.94

The renal urodilatin system: clinical implications. Cardiovasc Res (2001) 0.94

A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int (2015) 0.93

Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One (2014) 0.86

Inhibition of the pacemaker current: a bradycardic therapy for off-pump coronary operations. Ann Thorac Surg (1998) 0.82

Time to start implementing Lean and Six Sigma in the catheterization laboratory. Cardiovasc Revasc Med (2016) 1.40

Exploring the Microbiome in Heart Failure. Curr Heart Fail Rep (2016) 0.80

Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects. Cardiovasc Ther (2017) 0.75

Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther (2016) 0.75